Study finds subcutaneous spesolimab reduces flares in patients with GPP.

The article present a study that demonstrates the efficacy of subcutaneous spesolimab, an interleukin-36 receptor antagonist, in reducing the risk of generalized pustular psoriasis (GPP) flares. It discusses that high-dose subcutaneous spesolimab significantly reduced GPP flares by 84% over 48 weeks, with potential implications for improved patient outcomes and the prevention of complications associated with this rare skin disease.